Evidence map›Paper›PMID 29192329›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients.

Julie Ryan Wolf, Charles E Heckler, Joseph J Guido, Anita R Peoples, Jennifer S Gewandter, Marilyn Ling, Vincent P Vinciguerra, Thomas Anderson, Lisa Evans, James Wade and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Natural and miscellaneous agents for the prevention of acute radiation dermatitis: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Guideline
  10. Trial
  11. Trial
  12. Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Trial
  13. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Julie Ryan WolfDepartment of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY, 14642, USA. julie_ryan@urmc.rochester.edu.ORCID http://orcid.org/0000-0002-0592-7820
Charles E HecklerURCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.
Joseph J GuidoURCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.
Anita R PeoplesURCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.
Jennifer S GewandterDepartment of Anesthesiology, University of Rochester Medical Center, Rochester, NY, USA.
Marilyn LingDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.
Vincent P VinciguerraNorth Shore-LIJ Cancer Institute, New Hyde Park, NY, USA.
Thomas AndersonColumbus NCORP, Columbus, OH, USA.
Lisa EvansSoutheast Clinical Oncology Research Consortium, Winston-Salem, NC, USA.
James WadeHeartland NCORP, Decatur, IL, USA.
Alice P PentlandDepartment of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY, 14642, USA.
Gary R MorrowURCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.
University of Rochester Medical Center · USColumbus Center · USHeartland Cancer Research · USSoutheast Clinical Oncology Research Consortium · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
National Cancer Institute R25CA102618National Cancer Institute UG1CA189961NCI NIH HHS R25 CA102618NCI NIH HHS UG1 CA189961
6 · The paper itself

Abstract

purposeDespite advances in medical technology, radiation dermatitis occurs in 95% of patients receiving radiation therapy (RT) for cancer. Currently, there is no standard and effective treatment for the prevention or control of radiation dermatitis. The goal of the study was to determine the efficacy of oral curcumin, one of the biologically active components in turmeric, at reducing radiation dermatitis severity (RDS) at the end of RT, using the RDS scale, compared to placebo.

methodsThis was a multisite, randomized, double-blinded, placebo-controlled trial of 686 breast cancer patients. Patients took four 500-mg capsules of placebo or curcumin three times daily throughout their prescribed course of RT until 1 week post-RT.

resultsA total of 686 patients were included in the final analyses (87.5% white females, mean age = 58). Linear mixed-model analyses demonstrated that curcumin did not reduce radiation dermatitis severity at the end of RT compared to placebo (B (95% CI) = 0.044 (- 0.101, 0.188), p = 0.552). Fewer curcumin patients with RDS > 3.0 suggested a trend toward reduced severity (7.4 vs. 12.9%, p = 0.082). Patient-reported changes in pain, symptoms, and quality of life were not statistically significant between arms.

conclusionsOral curcumin did not significantly reduce radiation dermatitis severity compared to placebo. The skin rating variation and broad eligibility criteria could not account for the undetectable therapeutic effect. An objective measure for radiation dermatitis severity and further exploration for an effective treatment for radiation dermatitis is warranted.

Indexed as

Administration, OralBreast NeoplasmsCurcuminDouble-Blind MethodFemaleHumansMiddle AgedQuality of LifeRadiodermatitisTreatment OutcomeCurcuminCancerCurcuminDermatitisRadiation therapySkin

Identifiers

PMID29192329
PMCPMC5876157
OpenAlexW2772460351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.